NasdaqGS:SRPT

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities approaches for the treatment of rare diseases. More Details


Snowflake Analysis

Adequate balance sheet and slightly overvalued.


Similar Companies

Share Price & News

How has Sarepta Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SRPT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 17% a week.

Volatility Over Time: SRPT's weekly volatility has increased from 10% to 17% over the past year.


Market Performance


7 Day Return

10.9%

SRPT

4.5%

US Biotechs

0.3%

US Market


1 Year Return

-18.2%

SRPT

40.6%

US Biotechs

21.1%

US Market

Return vs Industry: SRPT underperformed the US Biotechs industry which returned 40.6% over the past year.

Return vs Market: SRPT underperformed the US Market which returned 21.1% over the past year.


Shareholder returns

SRPTIndustryMarket
7 Day10.9%4.5%0.3%
30 Day-45.3%6.8%3.3%
90 Day-29.8%27.2%14.2%
1 Year-18.2%-18.2%42.9%40.6%23.8%21.1%
3 Year47.1%47.1%28.8%22.1%45.0%35.4%
5 Year711.1%711.1%51.3%39.6%127.7%102.3%

Long-Term Price Volatility Vs. Market

How volatile is Sarepta Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Sarepta Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: SRPT ($96.76) is trading below our estimate of fair value ($371.59)

Significantly Below Fair Value: SRPT is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: SRPT is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: SRPT is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SRPT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SRPT is overvalued based on its PB Ratio (8.5x) compared to the US Biotechs industry average (4.3x).


Next Steps

Future Growth

How is Sarepta Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 20 analysts?

56.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SRPT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SRPT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SRPT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SRPT's revenue (29.6% per year) is forecast to grow faster than the US market (10.4% per year).

High Growth Revenue: SRPT's revenue (29.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: SRPT is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Sarepta Therapeutics performed over the past 5 years?

-31.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SRPT is currently unprofitable.

Growing Profit Margin: SRPT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SRPT is unprofitable, and losses have increased over the past 5 years at a rate of 31.1% per year.

Accelerating Growth: Unable to compare SRPT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SRPT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).


Return on Equity

High ROE: SRPT has a negative Return on Equity (-67.32%), as it is currently unprofitable.


Next Steps

  • Explore strong past performing companies in the Pharmaceuticals & Biotech industry.

Financial Health

How is Sarepta Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: SRPT's short term assets ($2.3B) exceed its short term liabilities ($378.4M).

Long Term Liabilities: SRPT's short term assets ($2.3B) exceed its long term liabilities ($1.5B).


Debt to Equity History and Analysis

Debt Level: SRPT's debt to equity ratio (78.5%) is considered high.

Reducing Debt: SRPT's debt to equity ratio has increased from 18.7% to 78.5% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable SRPT has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: SRPT is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 1.4% per year.


Next Steps

Dividend

What is Sarepta Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SRPT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SRPT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SRPT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SRPT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SRPT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure


CEO

Doug Ingram (57 yo)

3.58yrs

Tenure

US$1,387,072

Compensation

Mr. Douglas S. Ingram, also known as Doug, J.D., Esq., has been Chief Executive Officer and President of Sarepta Therapeutics, Inc. since June 26, 2017. Mr. Ingram serves as Director of Relay Therapeutics,...


CEO Compensation Analysis

Compensation vs Market: Doug's total compensation ($USD1.39M) is below average for companies of similar size in the US market ($USD6.22M).

Compensation vs Earnings: Doug's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Douglas Ingram
President3.58yrsUS$1.39m0.45%
$ 34.6m
William Ciambrone
Executive Vice President of Technical Operations1.17yrsUS$4.73mno data
David Howton
Consultant0.083yrUS$4.20m0.032%
$ 2.4m
Gilmore O'Neill
Executive VP of R&D and Chief Medical Officer2.58yrsUS$5.17m0.0093%
$ 713.2k
Ian Estepan
Executive VP0.083yrno data0.018%
$ 1.4m
Louise Rodino-Klapac
Executive VP & Chief Scientific Officer0.083yrno data0.0091%
$ 693.3k
Ryan Brown
VP, Global Chief Compliance Officer0.083yrno datano data
Diane Berry
Senior Vice President of Global Health Policy and Government & Patient Affairs1.33yrsno datano data
Joan Nickerson
Senior Vice President of Human Resources1.33yrsno datano data
Dallan Murray
Senior VP & Chief Commercial Officer0.083yrno datano data
Joseph Bratica
Controller & VP3.83yrsno data0.010%
$ 788.0k
Edward Kaye
3.58yrsUS$4.78mno data

1.3yrs

Average Tenure

56yo

Average Age

Experienced Management: SRPT's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Douglas Ingram
President3.58yrsUS$1.39m0.45%
$ 34.6m
John Martin
Independent Director1yrno datano data
M. Behrens
Independent Chairwoman5.75yrsUS$606.36k0.17%
$ 13.3m
Hans Wigzell
Chairman of Corporate Strategy Board & Independent Non-Employee Directorno dataUS$562.17k0.015%
$ 1.1m
Richard Barry
Independent Director5.58yrsUS$574.37k3.96%
$ 302.6m
Beverly Davidson
Member of Strategic & Scientific Advisory Board5.42yrsno datano data
Mary Gray
Independent Director2.08yrsUS$556.72k0.0046%
$ 352.0k
Louis Kunkel
Member of Strategic & Scientific Advisory Board5.42yrsno datano data
Claude Nicaise
Independent Non-Employee Director5.58yrsUS$561.33k0.0089%
$ 682.6k
Kenneth Fischbeck
Member of Strategic & Scientific Advisory Board3.83yrsno datano data
Matthew Wood
Member of Strategic & Scientific Advisory Board3.83yrsno datano data

4.6yrs

Average Tenure

67yo

Average Age

Experienced Board: SRPT's board of directors are considered experienced (4.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.9%.


Top Shareholders

Company Information

Sarepta Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Sarepta Therapeutics, Inc.
  • Ticker: SRPT
  • Exchange: NasdaqGS
  • Founded: 1980
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$7.636b
  • Shares outstanding: 78.91m
  • Website: https://www.sarepta.com

Number of Employees


Location

  • Sarepta Therapeutics, Inc.
  • 215 First Street
  • Suite 415
  • Cambridge
  • Massachusetts
  • 2142
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SRPTNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJun 1997
AB3ADB (Deutsche Boerse AG)YesCommon StockDEEURJun 1997
0L35LSE (London Stock Exchange)YesCommon StockGBUSDJun 1997
S1RP34BOVESPA (Bolsa de Valores de Sao Paulo)BDR EACH 20 REPR 1 COM NPVBRBRLOct 2020

Biography

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities appro...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/21 00:06
End of Day Share Price2021/01/20 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.